Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Ovarian cancer: a clinical challenge that needs some basic answers.

Lawrenson K, Gayther SA.

PLoS Med. 2009 Feb 3;6(2):e25. doi: 10.1371/journal.pmed.1000025. No abstract available.

2.

Differential gene expression analysis of ovarian cancer in a population isolate.

Grazio D, Pichler I, Fuchsberger C, Zolezzi F, Guarnieri P, Heidegger H, Scherer A, Engl B, Messini S, Egarter-Vigl E, Pramstaller PP.

Eur J Gynaecol Oncol. 2008;29(4):357-63.

PMID:
18714569
3.

Claudin 10 is a glandular epithelial marker in the chicken model as human epithelial ovarian cancer.

Seo HW, Rengaraj D, Choi JW, Ahn SE, Song YS, Song G, Han JY.

Int J Gynecol Cancer. 2010 Dec;20(9):1465-73.

PMID:
21370593
4.

Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers.

Dong Y, Kaushal A, Brattsand M, Nicklin J, Clements JA.

Clin Cancer Res. 2003 May;9(5):1710-20.

5.

Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.

Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y, Ishii N, Yanaihara N, Yamada K, Takikawa O, Kawaguchi R, Isonishi S, Tanaka T, Urashima M.

Clin Cancer Res. 2005 Aug 15;11(16):6030-9.

6.

Expression of NEU3 (plasma membrane-associated sialidase) in clear cell adenocarcinoma of the ovary: its relationship with T factor of pTNM classification.

Nomura H, Tamada Y, Miyagi T, Suzuki A, Taira M, Suzuki N, Susumu N, Irimura T, Aoki D.

Oncol Res. 2006;16(6):289-97.

PMID:
17476974
7.

Biomarkers of mucinous tumors of the ovary.

Samimi G, Ozbun L, Johnson ME, Mok SC, Birrer MJ.

Dis Markers. 2007;23(5-6):389-96. No abstract available.

8.

Down-regulation of dicer expression in ovarian cancer tissues.

Pampalakis G, Diamandis EP, Katsaros D, Sotiropoulou G.

Clin Biochem. 2010 Feb;43(3):324-7. doi: 10.1016/j.clinbiochem.2009.09.014. Epub 2009 Sep 25.

PMID:
19782670
9.

Gene-expression profiling in epithelial ovarian cancer.

Konstantinopoulos PA, Spentzos D, Cannistra SA.

Nat Clin Pract Oncol. 2008 Oct;5(10):577-87. doi: 10.1038/ncponc1178. Epub 2008 Jul 22. Review.

PMID:
18648354
10.

Signature of a silent killer: expression profiling in epithelial ovarian cancer.

Le Page C, Provencher D, Maugard CM, Ouellet V, Mes-Masson AM.

Expert Rev Mol Diagn. 2004 Mar;4(2):157-67. Review.

PMID:
14995903
11.

Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.

Shigemasa K, Tian X, Gu L, Tanimoto H, Underwood LJ, O'Brien TJ, Ohama K.

Oncol Rep. 2004 Jun;11(6):1153-9.

PMID:
15138549
12.

Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer.

Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, Lockhart DJ, Burger RA, Hampton GM.

Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1176-81.

13.

Expression and methylation status of 14-3-3 sigma gene can characterize the different histological features of ovarian cancer.

Kaneuchi M, Sasaki M, Tanaka Y, Shiina H, Verma M, Ebina Y, Nomura E, Yamamoto R, Sakuragi N, Dahiya R.

Biochem Biophys Res Commun. 2004 Apr 16;316(4):1156-62.

PMID:
15044106
14.

IGKC and prognosis in breast cancer.

Schmidt M, Micke P, Hengstler JG.

Clin Cancer Res. 2013 Jan 1;19(1):304. doi: 10.1158/1078-0432.CCR-12-2818. Epub 2012 Dec 11. No abstract available.

15.

EGRI and FOSB gene expressions in cancer stroma are independent prognostic indicators for epithelial ovarian cancer receiving standard therapy.

Kataoka F, Tsuda H, Arao T, Nishimura S, Tanaka H, Nomura H, Chiyoda T, Hirasawa A, Akahane T, Nishio H, Nishio K, Aoki D.

Genes Chromosomes Cancer. 2012 Mar;51(3):300-12. doi: 10.1002/gcc.21916. Epub 2011 Nov 17.

PMID:
22095904
16.

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.

Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I; Australian Ovarian Cancer Study Group, Gertig D, DeFazio A, Bowtell DD.

Clin Cancer Res. 2008 Aug 15;14(16):5198-208. doi: 10.1158/1078-0432.CCR-08-0196.

17.

IGKC and prognosis in breast cancer--response to Schmidt.

Whiteside TL, Ferrone S.

Clin Cancer Res. 2013 Jan 1;19(1):305. doi: 10.1158/1078-0432.CCR-12-3200. Epub 2012 Dec 11. No abstract available.

18.

Gene expression: protein interaction systems network modeling identifies transformation-associated molecules and pathways in ovarian cancer.

Bapat SA, Krishnan A, Ghanate AD, Kusumbe AP, Kalra RS.

Cancer Res. 2010 Jun 15;70(12):4809-19. doi: 10.1158/0008-5472.CAN-10-0447. Epub 2010 Jun 8.

19.

Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies.

Zamagni C, Wirtz RM, De Iaco P, Rosati M, Veltrup E, Rosati F, Capizzi E, Cacciari N, Alboni C, Bernardi A, Massari F, Quercia S, D'Errico Grigioni A, Dietel M, Sehouli J, Denkert C, Martoni AA.

Endocr Relat Cancer. 2009 Dec;16(4):1241-9. doi: 10.1677/ERC-08-0342. Epub 2009 Sep 11.

20.

[Clinical significance of two-tier grading system of ovarian serous carcinoma].

Zhang J, Guo XQ, Liu JS.

Zhonghua Fu Chan Ke Za Zhi. 2011 Oct;46(10):739-41. Chinese. No abstract available.

PMID:
22321346

Supplemental Content

Support Center